keyword
MENU ▼
Read by QxMD icon Read
search

Borderline tumors

keyword
https://www.readbyqxmd.com/read/28936153/management-and-treatment-recommendations-for-world-health-organization-grade-iii-and-iv-gliomas
#1
REVIEW
Abdullah K Altwairgi, Shanker Raja, Mohammed Manzoor, Sadeq Aldandan, Eyad Alsaeed, Ali Balbaid, Hussain Alhussain, Yassir Orz, Ahmed Lary, Abdullah A Alsharm
The treatment recommendations provided in this manuscript are intended to serve as a knowledge base for clinicians and health personals involved in treating patients with high-grade malignant glioma. In newly diagnosed patients, complete resection or biopsy is required for histological characterization of the tumor, which in turn is essential to decide the treatment strategy. In patients with good or borderline performance score, radiotherapy (RT), and chemotherapy are the preferred management. In patients with poor performance score, RT with best possible supportive care is the mainstay of the management...
July 2017: International Journal of Health Sciences
https://www.readbyqxmd.com/read/28935270/preoperative-c-reactive-protein-serum-levels-as-a-predictive-diagnostic-marker-in-patients-with-adnexal-masses
#2
Elisabeth Reiser, Stefanie Aust, Veronika Seebacher, Alexander Reinthaller, Samir Helmy-Bader, Richard Schwameis, Christoph Grimm, Stephan Polterauer
OBJECTIVE: To evaluate C-reactive protein (CRP) serum levels as a preoperative predictive marker for ovarian cancer in patients with adnexal masses. METHODS: CRP serum levels of 1843 adnexal masses and subsequent surgery were investigated (patients with benign ovarian tumors: n=1423; borderline tumor of the ovary [BTO]: n=83; EOC: n=337). Test characteristics and predictive values of CRP serum levels were investigated by univariate analysis and multivariate binary logistic regression models...
September 18, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28932807/brain-metastasis-in-advanced-serous-borderline-tumor-of-the-ovary-a-case-presentation
#3
Madhuri Martin, Rachel N Grisham, Gulisa Turashvili, Darragh F Halpenny, Carol A Aghajanian, Vicky Makker
•Brain metastasis is an extremely rare secondary site of ovarian cancer metastasis.•Serous borderline tumor with brain metastasis has not been previously reported.•This is a rare case of brain metastasis in a patient with advanced serous borderline tumor.
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28928856/the-putative-role-of-tp53-alterations-and-p53-expression-in-borderline-ovarian-tumors-correlation-with-clinicopathological-features-and-prognosis-a-mini-review
#4
REVIEW
Andrzej Semczuk, Marek Gogacz, Anna Semczuk-Sikora, Maciej Jóźwik, Tomasz Rechberger
Borderline ovarian tumors (BOTs) represent an independent group among ovarian malignancies, being diagnosed at clinical stage earlier than invasive ovarian carcinomas (OCs) and characterized by a rather favorable outcome after careful surgical management. Data published worldwide showed a substantial discordance of p53 expression in BOTs. The purpose of this work was to present the current status of knowledge on the significance of TP53 gene and p53 protein product alterations in BOTs. In general, higher p53 expression patterns were reported for ovarian malignancies compared to BOTs...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28927093/detailed-analysis-of-a-superficial-cd34-positive-fibroblastic-tumor-a-case-report-and-review-of-the-literature
#5
Kensaku Yamaga, Akihiro Fujita, Mari Osaki, Satoshi Kuwamoto, Naoko Ishiguro, Tadahito Yamamoto, Hideki Nagashima
Superficial cluster of differentiation (CD)34-positive fibroblastic tumor (SCPFT) is a rare mesenchymal neoplasm of borderline malignancy. It is characterized by a superficial location, marked cellular pleomorphism, an extremely low incidence of mitotic figures, and strong CD34 immunohistochemical positivity. As SCPFT is a recently described neoplasm, its characteristics are yet to be fully elucidated. To the best of our knowledge, no detailed studies regarding the imaging findings and cytogenetic analyses of SCPFTs exist...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28925490/multi-detector-spiral-ct-diagnosis-of-common-bile-duct-ampullary-carcinoma
#6
D-Z Zhao, Y Guo, Y-P Sun, H-M Liu, Z Zhang, Q-L Ma, Y-S Wang, C-L Chen
OBJECTIVE: The aim of this project was to study the imaging characteristics of multi-detector CT (MDCT) in different types of malignant tumor in the common bile duct ampulla. PATIENTS AND METHODS: We examined 30 cases of pancreatic head cancer, 35 of terminal cholangiocarcinoma, 26 of ampullary carcinoma, and 40 of benign lesions, all confirmed by pathology. We used 64-slice spiral CT plain scan and multi-phase enhanced scan with multi-planar reconstruction (MPR) and curved planar reconstruction (CPR) post-processing to obtain three-dimensional images...
August 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28923230/randomized-clinical-trials-in-pancreatic-cancer
#7
REVIEW
Neha Goel, Sanjay S Reddy
The management of pancreatic cancer has grown rapidly in the last decade. The Gastrointestinal Tumor Study Group trial in 1985 supported postoperative chemoradiation, and a more recent study recommended 6 months of adjuvant gemcitabine and capecitabine or monotherapy with gemcitabine or fluorouracil plus folinic acid, in the absence of neoadjuvant therapy. Clinicians are now studying the role of targeted therapy in pancreatic cancer and neoadjuvant chemotherapy in resectable, borderline resectable, and locally advanced pancreatic cancer...
October 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/28915673/prognositic-value-of-cd73-adenosinergic-pathway-in-solid-tumor-a-meta-analysis-and-systematic-review
#8
Rong Wang, Yingying Zhang, Xia Lin, Yalin Gao, Ying Zhu
CD73 is a glycosylphosphatidylinositol (GPI) anchored cell surface protein that is encoded by NT5E gene, plays multiple roles in tumor processes. Previous studies have presented a potential value of CD73 served as a detectable biomarker for prognosis of several solid tumors, but the results were more controversially. A comprehensive meta-analysis was conducted to precisely evaluate the prognostic role of CD73 in solid tumors. The included studies were searched in PubMed, Web of Science and EBSCO from Jan 1990 to Jan 2016...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28913760/impact-of-histopathology-tumor-infiltrating-lymphocytes-and-adjuvant-chemotherapy-on-prognosis-of-triple-negative-breast-cancer
#9
Roberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, Judith A Gilbert, Victoria Cafourek, David W Hillman, Ahmed Elkhanany, Margaret Akinhanmi, Jenna Lilyquist, Abigail Thomas, Vivian Negron, Judy C Boughey, Minetta C Liu, James N Ingle, Krishna R Kalari, Fergus J Couch, Daniel W Visscher, Matthew P Goetz
BACKGROUND: Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implications in systemically untreated patients remain unknown. METHODS: From a cohort of 9982 women with surgically treated non-metastatic breast cancer, all patients with clinically reported ER-negative/borderline (≤10%) disease were selected for central assessment of ER/PR/HER2, histopathology, Ki-67, and TILs...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28906309/cancer-stem-cell-related-marker-nanog-expression-in-ovarian-serous-tumors-a-clinicopathological-study-of-159-cases
#10
Nataša Kenda Šuster, Snježana Frković Grazio, Irma Virant-Klun, Ivan Verdenik, Špela Smrkolj
OBJECTIVE: The objectives of this study were to assess cancer stem cell-related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma. METHODS: NANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and the percentage of positive cells in tumor samples...
September 13, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28899828/borderline-ovarian-tumor-in-the-pediatric-and-adolescent-population-a-case-series-and-literature-review
#11
Krista J Childress, Ninad Mohan Patil, Jodi A Muscal, Jennifer E Dietrich, Rajkumar Venkatramani
STUDY OBJECTIVE: To determine the diagnosis, management, and outcome for children and adolescents with borderline ovarian tumor (BOT), To provide a review of the literature on BOT in children and adolescents. DESIGN: A retrospective cohort study of females under age 21 diagnosed with BOT between January 2001 and May 2016. SETTING: Texas Children's Hospital, Houston, Texas PARTICIPANTS: Fourteen patients (ages 12 to 18) diagnosed with BOT. MAIN OUTCOME MEASURES: Clinical presentation, pre-operative characteristics, surgical technique, cancer stage, histology, treatment, recurrence...
September 9, 2017: Journal of Pediatric and Adolescent Gynecology
https://www.readbyqxmd.com/read/28894578/giant-gastrointestinal-stromal-tumor-of-the-vermiform-appendix-a-case-report
#12
Manabu Kaneko, Kazushige Kawai, Koji Murono, Takeshi Nishikawa, Kazuhito Sasaki, Kensuke Otani, Koji Yasuda, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Soichiro Ishihara, Akimasa Hayashi, Aya Shinozaki-Ushiku, Masashi Fukayama, Toshiaki Watanabe
Gastrointestinal stromal tumors (GISTs) of the vermiform appendix are rare, measuring <3 cm in 82.4% of the reported cases. Neoadjuvant therapy with the receptor tyrosine kinase inhibitor imatinib mesylate has the potential to improve resectability and organ preservation rates in locally advanced or metastatic/recurrent GISTs. We herein report the case of a 67-year-old male patient with an unusually large GIST (22 cm in diameter) of uncertain origin in the right lower abdominal quadrant, with a solitary peritoneal metastasis...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28892220/annual-report-of-the-committee-on-gynecologic-oncology-japan-society-of-obstetrics-and-gynecology-patient-annual-report-for-2014-and-treatment-annual-report-for-2009
#13
Toshiaki Saito, Fumiaki Takahashi, Hidetaka Katabuchi
The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. We present the Patient Annual Report for 2014 and the Treatment Annual Report for 2009. Data on 7436 patients with cervical cancer, 9673 with endometrial cancer, 5924 with ovarian cancer, and 1909 with ovarian borderline tumor for whom treatment was initiated in 2014 were summarized in the Patient Annual Report. Stage I accounted for 55.6%, stage II for 22.9%, stage III for 10.2%, and stage IV for 11...
September 11, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28873354/mutation-of-nras-is-a-rare-genetic-event-in-ovarian-low-grade-serous-carcinoma
#14
Deyin Xing, Yohan Suryo Rahmanto, Felix Zeppernick, Charlotte G Hannibal, Susanne K Kjaer, Russell Vang, Ie-Ming Shih, Tian-Li Wang
Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of serous borderline tumor (SBT) to invasive low grade serous carcinoma (LGSC) remains largely unknown. While mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression...
September 2, 2017: Human Pathology
https://www.readbyqxmd.com/read/28866783/what-is-the-impact-of-stromal-microinvasion-on-oncologic-outcomes-in-borderline-ovarian-tumors-a-multicenter-case-control-study
#15
Gokhan Boyraz, Mehmet Coskun Salman, Murat Gultekin, Nazlı Topfedaisi Ozkan, Hasan H Uckan, Kemal Gungorduk, Varol Gulseren, Hulya Ayik, Tayfun Toptas, Oguzhan Kuru, Hamdullah Sozen, Anıl Erturk, Nejat Ozgul, Mehmet Mutlu Meydanlı, Muzaffer Sanci, Taner Turan, Tayfun Gungor, Tayup Simsek, Samet Topuz, Kunter Yuce
PURPOSE: To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs. METHODS: A retrospective multicenter case-control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis...
September 2, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28863071/an-ovarian-adenocarcinoma-with-combined-low-grade-serous-and-mesonephric-morphologies-suggests-a-m%C3%A3-llerian-origin-for-some-mesonephric-carcinomas
#16
David B Chapel, Nancy M Joseph, Thomas Krausz, Ricardo R Lastra
Mesonephric carcinomas are rare adenocarcinomas of the female genital tract that occur most commonly in the uterine cervix. They are classically thought to arise from benign mesonephric remnants, and are rarely reported at other sites in the gynecologic tract. Here we present an interesting biphenotypic ovarian adenocarcinoma with intimately associated but distinct components of both low-grade serous carcinoma and mesonephric-like carcinoma. A serous borderline tumor was present adjacent to the invasive carcinoma, and no benign mesonephric precursors were identified...
August 31, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28860006/combining-a-symptom-index-ca125-and-he4-triple-screen-to-detect-ovarian-cancer-in-women-with-a-pelvic-mass
#17
Barbara A Goff, Kathy Agnew, Moni Blazej Neradilek, Heidi J Gray, John B Liao, Renata R Urban
OBJECTIVES: To assess a simple algorithm of CA125, HE4 and Symptom Index to predict ovarian cancer in women with a pelvic mass. METHODS: This was a prospective study of women referred to a gynecologic oncology clinic for surgical evaluation of a pelvic mass. Preoperatively, women completed a SI and had serum markers drawn. Results were correlated with pathology. A triple screen was considered positive if at least 2 of the 3 markers were abnormal (positive SI, CA125≥35U/mL, HE4≥140pmol/L)...
August 28, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28853527/-low-grade-ovarian-cancer
#18
REVIEW
Yakir Segev, Anis Kaldawy, Ron Auslender, Ofer Lavie
According to the new and reproducible grading system of the MD Anderson Cancer Center (MDACC), low grade serous cancer (LGSC) differs greatly from the commonly known high grade serous cancer (HGSC). Pathology speaking, LGSC has less mitotic index; the grade of nuclear atypia is low to intermediate. Genetically speaking, these tumors tend to show mutation in the mitogen-activated protein kinase (MAPK) pathway, mainly in the KRAS and BRAF genes, resulting in uncontrolled proliferation; however, it seems that the presence of this mutation might be related to a better prognosis compared to their absence...
August 2017: Harefuah
https://www.readbyqxmd.com/read/28853064/receptor-activator-of-nuclear-transcription-factor-nf-%C3%AE%C2%BAb-rank-its-ligand-rankl-and-natural-inhibitor-of-rankl-osteoprotegerin-opg-in-the-blood-serum-of-patients-with-primary-bone-tumors
#19
N E Kushlinskii, E S Gershtein, Yu N Solov'ev, Yu S Timofeev, I V Babkina, A O Dolinkin, A A Zuev, O I Kostyleva
The content of components of the RANK/RANKL/OPG system, the key regulator of homeostasis in the bone tissue, in blood serum samples from 199 patients with primary bone neoplasms and 131 practically healthy volunteers was measured by ELISA. Borderline giantcell tumor of the bone with high osteoclastogenic and osteolytic activity is characterized by an increase in the level of all components of this system and highest ratio of sRANKL/OPG in the blood serum. Study indexes in patients with various benign neoplasms and tumor-like bone lesions were lower than in patients with giant-cell tumor...
August 2017: Bulletin of Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28844626/associations-of-tumor-necrosis-factor-%C3%AE-and-interleukin-1%C3%AE-levels-and-polymorphisms-with-post-stroke-depression
#20
Jae-Min Kim, Hee-Ju Kang, Ju-Wan Kim, Kyung-Yeol Bae, Sung-Wan Kim, Joon-Tae Kim, Man-Seok Park, Ki-Hyun Cho
OBJECTIVE: Proinflammatory cytokines have been implicated in the pathophysiology of post-stroke depression (PSD), and their production levels are influenced by the transcriptional activity of genetic polymorphisms. The present study aimed to investigate the roles of tumor necrosis factor (TNF)-α and interleukin (IL)-1β in the serum on the risk of PSD while taking into account the TNF-α -850C/T and -308G/A polymorphisms and the IL-1β -511C/T and +3953C/T polymorphisms. METHODS: A total of 286 patients were evaluated at 2 weeks post stroke and 222 (78%) of these patients were followed up 1 year later...
July 25, 2017: American Journal of Geriatric Psychiatry
keyword
keyword
49417
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"